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Reply
We thank Dr. Völzke for his comments on our recent publication
describing the cardiovascular manifestations of hyperthyroidism
before and after antithyroid therapy (1). This age- and gender-
matched case-control study of a consecutive series of 393 subjects
presenting with overt hyperthyroidism aimed to define the cardio-
vascular symptoms, signs, and dysrhythmias found in hyperthy-
roidism and to compare results with euthyroid control subjects.
After a mean follow-up period of 5.5 years after presentation, 26
hyperthyroid subjects had died compared with 12 age- and
gender-matched controls (p  0.01). We state in our discussion
that “the number of deaths remained too small to determine
whether excess mortality [not a primary end point of our study]
was specifically vascular in nature.” We agree that the higher
prevalence of smoking in our hyperthyroid subjects may be a
confounder in terms of the mortality observed; however, there was
no significant difference in prevalence of diabetes between subjects
and controls. Whereas Dr. Völzke asserts that our hyperthyroid
subjects may have been selected because they were seen in a
university hospital setting, we consider this unlikely as our hospital
serves as the general referral site for hyperthyroidism, rather than
as a specialist referral center.
In summarizing previous reports examining the relationship
between hyperthyroidism and mortality, Dr. Völzke failed to make
the critical distinction between studies of overt hyperthyroidism
and those examining subclinical hyperthyroidism (defined bio-
chemically as low serum thyrotropin with normal circulating
thyroid hormone concentrations). We have previously reported in
2 large cohort studies that overt hyperthyroidism is associated with
excess all-cause and vascular mortality (2,3) findings in accord with
a large cohort study in the U.S. (4) and together providing good
evidence that the cardiovascular complications of overt thyroid
hormone excess (1) translate into excess vascular mortality. Unsur-
prisingly, results are less clear-cut for subclinical hyperthyroidism,
which represents a much lesser degree of thyroid hormone excess.
Increasing evidence from several large studies supports a link
between subclinical hyperthyroidism and atrial fibrillation (5–7).
We have previously reported that a low serum thyrotropin result is,
in turn, associated with increased mortality after follow-up of 10
years (8) however, a higher rate of coronary heart disease and
all-cause mortality observed by Cappola et al. during follow-up of
subclinical hyperthyroidism was not significant (5). Likewise,
Walsh et al. (9) found no adverse outcomes in a prospective study
of subclinical hyperthyroid subjects (9).
A very different study in subjects aged 73 to 94 years by van den
Beld et al. (10)—incorrectly cited by Dr. Völzke as evidence
against an association between subclinical hyperthyroidism and
mortality—examined the relationship between circulating thyroid
hormone concentrations and physical performance scores, other
markers of muscle function, and bone density. That study revealed
an association between higher serum T4 and reduced physical
performance score. Gussekloo et al. (11) studied very elderly
subjects from the Leiden cohort (85 to 89 years) and reported
increased hazard ratios for mortality for increasing increments of
serum-free T4, as well as reduced mortality associated with
subclinical hypothyroidism, not hyperthyroidism as suggested by
Dr. Völzke.
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